J&J For A Slowing Economy
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $263.04 +3.57%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: +2.9%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: +2.9%
Join SI Premium – FREE
CONTRIBUTOR Yaser Anwar http://equityinvestmentideas.blogspot.com
Healthcare behemoth Johnson & Johnson (NYSE: JNJ) is a great pick for riding out a slowing economy, says Barron�s.
The article cites J&J�s diversification in three separate sectors of the health care industry: prescription drugs, devices and diagnostics, and consumer health care. J&J owns well-known brands such as Band-Aids, Tylenol and will soon add Lubriderm and Listerine thanks to an acquisition of Pfizer�s consumer health care unit.
Matthew D. McCormick, portfolio manager at Bahl & Gaynor, points out to Barrons that even in the event of a recession consumers will need to buy the "bare necessities." McCormick calls J&J, "a diversified play on almost every health care product out there."
Barron�s also points out that J&J is looking expected to deliver solid earnings for an established company. J&J is expected to earn $10.9 billion, or $3.69 a share this year, a 6 percent gain from last year�s $3.49 a share. According to Barron�s, analysts are looking for earnings of $4.01 in 2007 and $4.28 in 2008.
J&J trades at an historic multiple of 19.4 times forward earnings and is selling at just 16 times future earnings, says Barron�s. It also has a lower multiple than many of its competitors. It's current price to cash flow ratio of 15 is also lower than its historic average of 18.
"When you see a company with a pretty good franchise in three areas trading at low historic values � it�s opportunistic to buy it," George Foley, manager of large-cap and core value portfolios at Glenmede, tells Barron�s. Glenmede holds stock in J&J.
Based on these valuations, J&J�s stock could be worth $77 a share, says Citigroup analyst Matthew Dodds. That would be a 19 percent gain over its current share price of $64.80.
http://equityinvestmentideas.blogspot.com
Healthcare behemoth Johnson & Johnson (NYSE: JNJ) is a great pick for riding out a slowing economy, says Barron�s.
The article cites J&J�s diversification in three separate sectors of the health care industry: prescription drugs, devices and diagnostics, and consumer health care. J&J owns well-known brands such as Band-Aids, Tylenol and will soon add Lubriderm and Listerine thanks to an acquisition of Pfizer�s consumer health care unit.
Matthew D. McCormick, portfolio manager at Bahl & Gaynor, points out to Barrons that even in the event of a recession consumers will need to buy the "bare necessities." McCormick calls J&J, "a diversified play on almost every health care product out there."
Barron�s also points out that J&J is looking expected to deliver solid earnings for an established company. J&J is expected to earn $10.9 billion, or $3.69 a share this year, a 6 percent gain from last year�s $3.49 a share. According to Barron�s, analysts are looking for earnings of $4.01 in 2007 and $4.28 in 2008.
J&J trades at an historic multiple of 19.4 times forward earnings and is selling at just 16 times future earnings, says Barron�s. It also has a lower multiple than many of its competitors. It's current price to cash flow ratio of 15 is also lower than its historic average of 18.
"When you see a company with a pretty good franchise in three areas trading at low historic values � it�s opportunistic to buy it," George Foley, manager of large-cap and core value portfolios at Glenmede, tells Barron�s. Glenmede holds stock in J&J.
Based on these valuations, J&J�s stock could be worth $77 a share, says Citigroup analyst Matthew Dodds. That would be a 19 percent gain over its current share price of $64.80.
http://equityinvestmentideas.blogspot.com
You May Also Be Interested In
- Increasing unusual put volume: XLI EQT ARKG ROST WEN KOS BKLN UUP DB DJ JNJ LOW FVRR
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- AI as governor: the $6.75 trillion case for replacing politicians
Create E-mail Alert Related Categories
ContributorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
